A. Hoffenbach

发表

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

C. Moste, Marie-Clotilde Bernard, Catherine Caillet, 2010, Vaccine.

Improving seasonal and pandemic influenza vaccines

M. Saville, A. Hoffenbach, G. Marsh, 2008, Influenza and other respiratory viruses.

Randomised Study of the Possible Adjuvant Effect of BCG Vaccine on the Immunogenicity of Diphtheria-Tetanus-Acellular Pertussis Vaccine in Senegalese Infants

H. Salomón, J. Trape, S. Pinchinat, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

T. Vesikari, Stéphanie Pépin, M. Denis, 2012, Human vaccines & immunotherapeutics.

HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.

M. Kieny, P. Froussard, M. Kaczorek, 1992, AIDS research and human retroviruses.

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.

S. Halperin, F. Diaz-Mitoma, D. Radley, 2009, Vaccine.

Safety and Immunogenicity of Two Formulations of a Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus-Haemophilus influenzae b Conjugate-Hepatitis B Vaccine in 15 to 18 Month-Old Children

J. Langley, S. Halperin, D. Radley, 2005, Human vaccines.

Lot-to-Lot Consistency of a Combined Hexavalent Diptheria-Tentanus-Acellular-Pertussis, Hepatitis B, Inactivated Polio and Haemophilus b Conjugate Vaccine, Adminstered to Healthy Chilean Infants at 2, 4 and 6 Months of Age

M. Levine, L. Hessel, F. Schödel, 2005, Human vaccines.

Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants

L. Hessel, F. Schödel, E. Vidor, 2000, The Pediatric infectious disease journal.

Haemophilus influenzae Type b Vaccine: Reconstitution of Lyophilised PRP-T Vaccine with a Pertussis-containing Paediatric Combination Vaccine, or a Change in the Primary Series Immunisation Schedule, May Modify the Serum Anti-PRP Antibody Responses

E. Vidor, M. Fletcher, A. Hoffenbach, 2001, Current medical research and opinion.

Bacillary growth, interleukin 2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with Mycobacterium lepraemurium.

A. Hoffenbach, M. Bach, 1986, Cellular immunology.

Strain variation of lymphokine production and specific antibody secretion in mice infected with Mycobacterium lepraemurium.

P. Lagrange, A. Hoffenbach, M. Bach, 1985, Cellular immunology.

A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.

M. Levine, G. Kanra, P. Reinert, 2004, Vaccine.

Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of age.

P. Minini, J. Liese, B. Belohradsky, 2001, Vaccine.

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.

M. Granström, B. Claesson, A. Hoffenbach, 1998, The Pediatric infectious disease journal.

Pediatric Combination Vaccines

S. Plotkin, E. Vidor, A. Hoffenbach, 1999 .

New acellular pertussis-containing paediatric combined vaccines.

H. Salomón, S. Wood, A. Hoffenbach, 1999, Vaccine.

Enhancement of HIV‐specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment

P. Sansonetti, D. Chevrier, G. Dadaglio, 1992, Clinical and experimental immunology.

Specific detection of anti-HBc antibodies with an enzyme immunoassay using recombinant HBcAg and monoclonal antibodies.

A. Hoffenbach, G. Sommé, C. Trepo, 1993, Journal of virological methods.

Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination.

S. Wain-Hobson, G. Dadaglio, P. Langlade‐Demoyen, 1989, Immunodeficiency reviews.

Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.

M. Levine, K. Kotloff, R. Lagos, 1998, The Pediatric infectious disease journal.

HIV-specific cytotoxic T lymphocytes and their possible implications in the future vaccine against AIDS.

P. Langlade‐Demoyen, A. Hoffenbach, 1989, Research in immunology.

Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in Mycobacterium lepraemurium infection

P. Lagrange, A. Hoffenbach, M. Bach, 1983, Infection and immunity.

A monoclonal antibody against Mycobacterium lepraemurium which recognizes a cross-reacting mycobacterial antigen.

A. Hoffenbach, M. Bach, 1983, Annales d'immunologie.

Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.

B. Flageul, D. Wallach, A. Hoffenbach, 1986, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Multiple subsets of HIV‐specific cytotoxic T lymphocytes in humans and in mice

B. Guy, B. Autran, M. Kieny, 1989, European journal of immunology.

Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes.

B. Autran, S. Wain-Hobson, G. Dadaglio, 1988, Journal of immunology.

Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsid

C. Trépo, K. Mabrouk, J. Sabatier, 1993, Journal of medical virology.

Mechanisms of T-cell unresponsiveness in leprosy.

P. Lagrange, D. Wallach, A. Hoffenbach, 1983, Annales d'immunologie.

Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

B. Autran, G. Dadaglio, P. Langlade‐Demoyen, 1989, Journal of immunology.

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

S. Mboup, F. Simondon, I. Iteman, 1997, Vaccine.

Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens.

A. Hoffenbach, J. Vose, 1999, Biologicals : journal of the International Association of Biological Standardization.

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.

S. Halperin, F. Diaz-Mitoma, D. Radley, 2011, Vaccine.

Influence of dose and route of Mycobacterium lepraemurium inoculation on the production of interleukin 1 and interleukin 2 in C57BL/6 mice

P. Lagrange, A. Hoffenbach, M. Bach, 1984, Infection and immunity.

Synthetic peptides as antigens for detection by ELISA of anti-HBc antibodies in patients infected by hepatitis B virus (HBV)

K. Mabrouk, J. Sabatier, A. Hoffenbach, 1991 .

E. Vidor, M. Fletcher, A. Hoffenbach, 2001, Current medical research and opinion.